media – Page 606 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Do Children’s Antibiotics Lead to Type 1 Diabetes or Celiac Disease?

In a recent study, researchers investigated whether there is a link between children’s antibiotics and the rise of autoimmune diseases such as type 1 diabetes and celiac disease.
- Source: medicalnewsbulletin
- 624
- November 13, 2017
antibiotics autoimmune celiac diabetes Researches
Novartis posts eye drug data amid play for Eylea’s turf

Novartis’s bid to move in on Bayer’s and Regeneron’s eye-drug turf was buoyed on Friday by data showing patients on the Swiss drugmaker’s new RTH258 drug showed less disease activity than those on its rivals’ drug Eylea.
- Source: reuters
- 440
- November 13, 2017
active disease AMD Company Insight RTH258
Robots and AI Will Take Over These 3 Medical Niches First

We’re no stranger to robotics in the medical field. Robot-assisted surgery is becoming more and more common. Many training programs are starting to include robotic and virtual reality scenarios to provide hands-on training for students without putting patients at risk.
- Source: singularityhub
- 504
- November 13, 2017
Artificial Intelligence Market Views robotics surgery
Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

Merck KGaA’s pharma group is taking one more step in a long journey toward rehabbing its rep in the R&D field this weekend. Company execs turned up at the ACR scientific conference in San Diego to roll out a promising look at some key Phase II osteoarthritis data — which comes with a critical caveat.
- Source: Endpts
- 645
- November 13, 2017
Merck osteoarthritis R&D sprifermin
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)

Seattle Genetics, Inc. (SGEN) announced that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and MF are the most common subtypes of cutaneous T-cell lymphoma (CTCL).
- Source: finance.yahoo
- 470
- November 13, 2017
ADCETRIS anaplastic large cell lymphoma FDA
Dynavax Announces FDA Approval of HEPLISAV-B™ for Prevention of Hepatitis B in Adults

Dynavax Technologies Corporation (NASDAQ: DVAX) announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.
- Source: investors.dynavax
- 565
- November 13, 2017
FDA hepatitis B Heplisav-B
Guidance for Visiting Foreign Clients (Part Ⅱ)

After reading part 1 of our series Guidance for Visiting Foreign Clients you should probably know how to prepare before visiting foreign clients. In part 2 we give you more tips on how conduct your meeting for a more successful outcome.
- Source: Ddu
- 908
- November 10, 2017
clients Ddu College
Merck Receives FDA Approval of PREVYMIS™ (letermovir)

Merck & Co., Inc. (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved PREVYMIS™ (letermovir) once-daily tablets for oral use and injection for intravenous infusion. PREVYMIS is indicated for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).
- Source: finance.yahoo
- 1,107
- November 10, 2017
CMV FDA HSCT New Approvals
Novartis reports positive results from Phase III trial of Kisqali® (ribociclib) combination therapy

Novartis announced positive topline results from the global MONALEESA-7 trial, the second Phase III trial of Kisqali® (ribociclib) in advanced or metastatic breast cancer. The MONALEESA-7 trial met its primary endpoint of progression-free survival (PFS) in premenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.
- Source: Novartis
- 809
- November 10, 2017
breast cancer Clinical Trials Kisqali Phase
With 2-pronged filing, Novartis’ CAR-T med Kymriah aims to jump intoEurope with both feet

Novartis is blazing ahead with its bid to take its new CAR-T therapy, Kymriah, into new realms with a double-pronged approval application in Europe.
- Source: Fiercepharma
- 512
- November 10, 2017
CAR-T therapy Kymriah Novarti

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.